Effects of everolimus on macrophage-derived foam cell behavior

Cardiovascular Revascularization Medicine

Volumn 15, Issue 5, 2014, Pages 269-277

  Hsu, Steven ^a   Koren, Eugen ^a   Chan, Yen ^a   Koscec, Mirna ^a   Sheehy, Alexander ^a   Kolodgie, Frank ^b   Virmani, Renu ^b   Feder, Debra ^a  

^a ABBOTT VASCULAR   (United States)

^b CVPATH INSTITUTE   (United States)

Author keywords

Atherosclerosis; Drug eluting stents; Everolimus; Foam cells

Indexed keywords

ACETYL LOW DENSITY LIPOPROTEIN; CLUSTERIN; EVEROLIMUS; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; SURVIVIN; TUMOR NECROSIS FACTOR ALPHA; CARDIOVASCULAR AGENT; RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATHEROMA; AUTOPHAGY; CELL DEATH; CELL FUNCTION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ELUTING STENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FOAM CELL; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RABBIT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; SUPERNATANT; TISSUE SECTION; UMBILICAL VEIN ENDOTHELIAL CELL; ANALOGS AND DERIVATIVES; CELL DIFFERENTIATION; CELL LINE; CHEMICALLY INDUCED; CYTOLOGY; DRUG EFFECTS; NECROSIS;

APOPTOSIS; CARDIOVASCULAR AGENTS; CELL DIFFERENTIATION; CELL LINE; DRUG-ELUTING STENTS; FOAM CELLS; HUMANS; MACROPHAGES; NECROSIS; SIROLIMUS;

EID: 84908356387     PISSN: 15538389     EISSN: 18780938     Source Type: Journal    
DOI: 10.1016/j.carrev.2014.05.007     Document Type: Article

References (54)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
2. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
3. Hansson G.K., Robertson A.K., Soderberg-Naucler C. Inflammation and atherosclerosis. Annu Rev Pathol 2006, 1:297-329.
4. Schuler W., Sedrani R., Cottens S., Haberlin B., Schulz M., Schuurman H.J., et al. Sdz rad, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997, 64:36-42.
5. Carrera A.C. Tor signaling in mammals. J Cell Sci 2004, 117:4615-4616.
6. O'Reilly T., McSheehy P.M. Biomarker development for the clinical activity of the mtor inhibitor everolimus (rad001): processes, limitations, and further proposals. Transl Oncol 2010, 3:65-79.
7. Lavigne M.C., Grimsby J.L., Eppihimer M.J. Antirestenotic mechanisms of everolimus on human coronary artery smooth muscle cells: inhibition of human coronary artery smooth muscle cell proliferation, but not migration. J Cardiovasc Pharmacol 2012, 59:165-174.
8. Tsuchiya Y., Lansky A.J., Costa R.A., Mehran R., Pietras C., Shimada Y., et al. Effect of everolimus-eluting stents in different vessel sizes (from the pooled future i and ii trials). Am J Cardiol 2006, 98:464-469.
9. Garg S., Serruys P.W. Coronary stents: current status. J Am Coll Cardiol 2010, 56:S1-S42.
10. Gomez-Lara J., Brugaletta S., Farooq V., Onuma Y., Diletti R., Windecker S., et al. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography. JACC Cardiovasc Interv 2011, 4:1271-1280.
11. Cole O.J., Shehata M., Rigg K.M. Effect of sdz rad on transplant arteriosclerosis in the rat aortic model. Transplant Proc 1998, 30:2200-2203.
12. Farb A., John M., Acampado E., Kolodgie F.D., Prescott M.F., Virmani R. Oral everolimus inhibits in-stent neointimal growth. Circulation 2002, 106:2379-2384.
13. Matsumoto Y., Hof A., Baumlin Y., Hof R.P. Differential effect of cyclosporine a and sdz rad on neointima formation of carotid allografts in apolipoprotein e-deficient mice. Transplantation 2003, 76:1166-1170.
14. Mueller M.A., Beutner F., Teupser D., Ceglarek U., Thiery J. Prevention of atherosclerosis by the mtor inhibitor everolimus in ldlr-/- mice despite severe hypercholesterolemia. Atherosclerosis 2008, 198:39-48.
15. Verheye S., Martinet W., Kockx M.M., Knaapen M.W., Salu K., Timmermans J.P., et al. Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol 2007, 49:706-715.
16. Martinet W., Verheye S., De Meyer G.R. Everolimus-induced mtor inhibition selectively depletes macrophages in atherosclerotic plaques by autophagy. Autophagy 2007, 3:241-244.
17. Martinet W., Verheye S., De Meyer G.R. Selective depletion of macrophages in atherosclerotic plaques via macrophage-specific initiation of cell death. Trends Cardiovasc Med 2007, 17:69-75.
18. Baetta R., Granata A., Canavesi M., Ferri N., Arnaboldi L., Bellosta S., et al. Everolimus inhibits monocyte/macrophage migration in vitro and their accumulation in carotid lesions of cholesterol-fed rabbits. J Pharmacol Exp Ther 2009, 328:419-425.
19. Seifert P., Pennington D., DoBrava E., Marcino J., Huibregtse B., Tellez A., et al. Everolimus-eluting stents inhibit neointimal macrophage foam cell accumulations in the coronary arteries of familial hypercholesterolemic swine. CRT Conference 2011.
20. Zhao H.Q., Nikanorov A., Virmani R., Schwartz L.B. Inhibition of experimental neointimal hyperplasia and neoatherosclerosis by local, stent-mediated delivery of everolimus. J Vasc Surg 2012, 56:1680-1688.
21. Warrior U., Fan Y., David C.A., Wilkins J.A., McKeegan E.M., Kofron J.L., et al. Application of quantigene nucleic acid quantification technology for high throughput screening. J Biomol Screen 2000, 5:343-352.
22. Canales R.D., Luo Y., Willey J.C., Austermiller B., Barbacioru C.C., Boysen C., et al. Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol 2006, 24:1115-1122.
23. Nakazawa G., Nakano M., Otsuka F., Wilcox J.N., Melder R., Pruitt S., et al. Evaluation of polymer-based comparator drug-eluting stents using a rabbit model of iliac artery atherosclerosis. Circ Cardiovasc Interv 2011, 4:38-46.
24. Yazdani S.K., Sheehy A., Nakano M., Nakazawa G., Vorpahl M., Otsuka F., et al. Preclinical evaluation of second-generation everolimus- and zotarolimus-eluting coronary stents. J Invasive Cardiol 2013, 25:383-390.
25. Hayden J.M., Brachova L., Higgins K., Obermiller L., Sevanian A., Khandrika S., et al. Induction of monocyte differentiation and foam cell formation in vitro by 7-ketocholesterol. J Lipid Res 2002, 43:26-35.
26. Wang X., Reape T.J., Li X., Rayner K., Webb C.L., Burnand K.G., et al. Induced expression of adipophilin mrna in human macrophages stimulated with oxidized low-density lipoprotein and in atherosclerotic lesions. FEBS Lett 1999, 462:145-150.
27. Wang X.Q., Yang K., He Y.S., Lu L., Shen W.F. Receptor mediated elevation in fabp4 levels by advanced glycation end products induces cholesterol and triacylglycerol accumulation in thp-1 macrophages. Lipids 2011, 46:479-486.
28. Blanc-Brude O.P., Teissier E., Castier Y., Leseche G., Bijnens A.P., Daemen M., et al. Iap survivin regulates atherosclerotic macrophage survival. Arterioscler Thromb Vasc Biol 2007, 27:901-907.
29. Pearse M.J., O'Bryan M., Fisicaro N., Rogers L., Murphy B., d'Apice A.J. Differential expression of clusterin in inducible models of apoptosis. Int Immunol 1992, 4:1225-1231.
30. Debure L., Vayssiere J.L., Rincheval V., Loison F., Le Drean Y., Michel D. Intracellular clusterin causes juxtanuclear aggregate formation and mitochondrial alteration. J Cell Sci 2003, 116:3109-3121.
31. tm everolimus-eluting coronary stent system: a preclinical assessment. J Interv Cardiol 2009, 22:S28-S40.
32. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994, 94:2493-2503.
33. Newby A.C., George S.J., Ismail Y., Johnson J.L., Sala-Newby G.B., Thomas A.C. Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes. Thromb Haemost 2009, 101:1006-1011.
34. Bjornheden T., Bondjers G. Oxygen consumption in aortic tissue from rabbits with diet-induced atherosclerosis. Arteriosclerosis 1987, 7:238-247.
35. Clarke M.C., Figg N., Maguire J.J., Davenport A.P., Goddard M., Littlewood T.D., et al. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med 2006, 12:1075-1080.
36. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol 2005, 25:2255-2264.
37. Jones C.B., Sane D.C., Herrington D.M. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003, 59:812-823.
38. Maiuri M.C., Zalckvar E., Kimchi A., Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007, 8:741-752.
39. Inbal B., Bialik S., Sabanay I., Shani G., Kimchi A. Dap kinase and drp-1 mediate membrane blebbing and the formation of autophagic vesicles during programmed cell death. J Cell Biol 2002, 157:455-468.
40. Martinet W., Schrijvers D.M., De Meyer G.R., Thielemans J., Knaapen M.W., Herman A.G., et al. Gene expression profiling of apoptosis-related genes in human atherosclerosis: upregulation of death-associated protein kinase. Arterioscler Thromb Vasc Biol 2002, 22:2023-2029.
41. Li Y., Gerbod-Giannone M.C., Seitz H., Cui D., Thorp E., Tall A.R., et al. Cholesterol-induced apoptotic macrophages elicit an inflammatory response in phagocytes, which is partially attenuated by the mer receptor. J Biol Chem 2006, 281:6707-6717.
42. Ait-Oufella H., Pouresmail V., Simon T., Blanc-Brude O., Kinugawa K., Merval R., et al. Defective mer receptor tyrosine kinase signaling in bone marrow cells promotes apoptotic cell accumulation and accelerates atherosclerosis. Arterioscler Thromb Vasc Biol 2008, 28:1429-1431.
43. Thorp E., Cui D., Schrijvers D.M., Kuriakose G., Tabas I. Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe-/- mice. Arterioscler Thromb Vasc Biol 2008, 28:1421-1428.
44. Serruys P.W., Ormiston J.A., Onuma Y., Regar E., Gonzalo N., Garcia-Garcia H.M., et al. A bioabsorbable everolimus-eluting coronary stent system (absorb): 2-year outcomes and results from multiple imaging methods. Lancet 2009, 373:897-910.
45. Kang W.C., Park Y.M., Shin K.C., Moon C.I., Lee K., Han S.H., et al. Comparison of edge vascular response after sirolimus- and paclitaxel-eluting stent implantation. Int J Cardiol 2013, 165:46-50.
46. Shao-liang C., Fei Y., Jun-jie Z., Zhi-zhong L., Shou-jie S., Xue-wen S., et al. Different edge effects of paclitaxel- and sirolimus-eluting stents on proximal and distal edges in patients with unstable angina: serial intravascular ultrasound analysis. Chin Med J 2009, 122:1603-1609.
47. Fagglotto A., Ross R., Harker L. Studies of hypercholesterolemia in the nonhuman primate, i. Changes that lead to fatty streak formation. Arteriosclerosis 1984, 4:323-340.
48. Schaffner T., Taylor K., Bartucci E.J., Fischer-Dzoga K., Beeson J.H., Glagov S., et al. Arterial foam cells with distinctive immunomorphologic and histochemical features of macrophages. Am J Pathol 1980, 100:57-80.
49. Gerrity R.G. The role of the monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol 1981, 103:181-190.
50. Skrinska V.A., Konieczkowski M., Gerrity R.G., Galang C.F., Rebec M.V. Suppression of foam cell lesions in hypercholesterolemic rabbits by inhibition of thromboxane a2 synthesis. Arteriosclerosis 1988, 8:359-367.
51. Klurfeld D.M. Identification of foam cells in human atherosclerotic lesions as macrophages using monoclonal antibodies. Arch Pathol Lab Med 1985, 109:445-449.
52. Koniari I., Mavrilas D., Papadaki H., Karanikolas M., Mandellou M., Papalois A., et al. Structural and biomechanical alterations in rabbit thoracic aortas are associated with the progression of atherosclerosis. Lipids Health Dis 2011, 10:125-133.
53. Thomas A.C., Sala-Newby G.B., Ismail Y., Johnson J.L., Pasterkamp G., Newby A.C. Genomics of foam cells and nonfoamy macrophages from rabbits identifies arginase-i as a differential regulator of nitric oxide production. Arterioscler Thromb Vasc Biol 2007, 27:571-577.
54. Wang Q., Pierson W., Sood P., Bol C., Cannon L., Gordon P., et al. Pharmacokinetic sub-study in the spirit iii randomized and controlled trial of xience v everolimus eluting coronary stent system. J Interv Cardiol 2010, 23:26-32.